| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Electrocardiography | 192 | 2026 | 969 | 29.840 |
Why?
|
| Myocardial Infarction | 166 | 2025 | 998 | 19.820 |
Why?
|
| ST Elevation Myocardial Infarction | 30 | 2024 | 116 | 11.400 |
Why?
|
| Myocardial Reperfusion Injury | 37 | 2022 | 130 | 9.080 |
Why?
|
| Myocardial Ischemia | 41 | 2026 | 307 | 7.520 |
Why?
|
| Bundle-Branch Block | 19 | 2025 | 41 | 5.850 |
Why?
|
| Acute Coronary Syndrome | 17 | 2024 | 235 | 5.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 27 | 2024 | 744 | 5.100 |
Why?
|
| Pacemaker, Artificial | 14 | 2024 | 193 | 4.450 |
Why?
|
| Myocardium | 43 | 2023 | 847 | 4.450 |
Why?
|
| Heptanoic Acids | 17 | 2008 | 79 | 3.560 |
Why?
|
| Atrial Fibrillation | 14 | 2026 | 736 | 3.410 |
Why?
|
| Cardiac Pacing, Artificial | 13 | 2024 | 135 | 3.390 |
Why?
|
| Glucosides | 9 | 2024 | 55 | 3.340 |
Why?
|
| Benzhydryl Compounds | 9 | 2024 | 79 | 3.270 |
Why?
|
| Pyrroles | 17 | 2008 | 188 | 3.260 |
Why?
|
| Coronary Occlusion | 8 | 2023 | 34 | 3.180 |
Why?
|
| Cardiotonic Agents | 11 | 2024 | 138 | 3.100 |
Why?
|
| Coronary Artery Disease | 21 | 2024 | 887 | 3.040 |
Why?
|
| Pericarditis | 7 | 2022 | 45 | 3.000 |
Why?
|
| Adenosine | 15 | 2022 | 116 | 2.990 |
Why?
|
| Thrombolytic Therapy | 37 | 2020 | 191 | 2.890 |
Why?
|
| Diabetes Mellitus, Type 2 | 17 | 2025 | 1457 | 2.890 |
Why?
|
| Heart Conduction System | 15 | 2026 | 162 | 2.770 |
Why?
|
| Coronary Angiography | 42 | 2024 | 449 | 2.680 |
Why?
|
| Coronary Vessels | 19 | 2023 | 521 | 2.620 |
Why?
|
| Thiazolidinediones | 11 | 2012 | 81 | 2.580 |
Why?
|
| Heart Rate | 13 | 2020 | 575 | 2.550 |
Why?
|
| Percutaneous Coronary Intervention | 12 | 2024 | 298 | 2.490 |
Why?
|
| Diagnosis, Differential | 38 | 2025 | 1874 | 2.490 |
Why?
|
| Humans | 337 | 2026 | 130611 | 2.480 |
Why?
|
| Cardiovascular Agents | 7 | 2023 | 87 | 2.480 |
Why?
|
| Cyclooxygenase 2 | 15 | 2016 | 121 | 2.460 |
Why?
|
| Cardiovascular Diseases | 16 | 2026 | 2111 | 2.440 |
Why?
|
| Platelet Aggregation Inhibitors | 13 | 2024 | 266 | 2.320 |
Why?
|
| Ventricular Function, Left | 21 | 2025 | 549 | 2.230 |
Why?
|
| Hypoglycemic Agents | 13 | 2025 | 477 | 2.140 |
Why?
|
| Diagnosis, Computer-Assisted | 6 | 2026 | 88 | 2.070 |
Why?
|
| Aspirin | 15 | 2022 | 211 | 1.960 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 5 | 2019 | 30 | 1.960 |
Why?
|
| Angioplasty, Balloon, Coronary | 24 | 2016 | 161 | 1.950 |
Why?
|
| Heart Atria | 9 | 2026 | 343 | 1.940 |
Why?
|
| Male | 218 | 2025 | 64659 | 1.890 |
Why?
|
| Anticoagulants | 9 | 2024 | 601 | 1.860 |
Why?
|
| Myocardial Reperfusion | 16 | 2011 | 53 | 1.860 |
Why?
|
| Heart Ventricles | 17 | 2021 | 749 | 1.840 |
Why?
|
| Chest Pain | 11 | 2023 | 122 | 1.830 |
Why?
|
| Defibrillators, Implantable | 5 | 2019 | 215 | 1.820 |
Why?
|
| Ventricular Dysfunction, Left | 13 | 2024 | 362 | 1.800 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 6 | 2022 | 43 | 1.770 |
Why?
|
| Coronary Stenosis | 6 | 2023 | 78 | 1.730 |
Why?
|
| Tetrazoles | 7 | 2021 | 70 | 1.660 |
Why?
|
| Echocardiography | 26 | 2022 | 1125 | 1.650 |
Why?
|
| Aged | 111 | 2025 | 20917 | 1.650 |
Why?
|
| Middle Aged | 140 | 2025 | 28454 | 1.610 |
Why?
|
| Animals | 96 | 2024 | 33743 | 1.550 |
Why?
|
| Heart | 18 | 2023 | 650 | 1.540 |
Why?
|
| Rats, Sprague-Dawley | 25 | 2022 | 1104 | 1.530 |
Why?
|
| Coronary Disease | 19 | 2007 | 623 | 1.520 |
Why?
|
| Inflammasomes | 7 | 2021 | 154 | 1.490 |
Why?
|
| Coronary Circulation | 17 | 2019 | 187 | 1.490 |
Why?
|
| Heart Failure | 17 | 2025 | 2328 | 1.450 |
Why?
|
| Rats | 29 | 2022 | 3366 | 1.400 |
Why?
|
| Tachycardia, Supraventricular | 3 | 2019 | 104 | 1.400 |
Why?
|
| Equipment Failure | 7 | 2017 | 122 | 1.390 |
Why?
|
| Nitric Oxide Synthase Type III | 12 | 2014 | 186 | 1.370 |
Why?
|
| Dipyridamole | 4 | 2021 | 19 | 1.350 |
Why?
|
| Tachycardia, Ventricular | 10 | 2020 | 257 | 1.320 |
Why?
|
| Lipoxins | 8 | 2016 | 11 | 1.290 |
Why?
|
| Anterior Wall Myocardial Infarction | 4 | 2018 | 11 | 1.260 |
Why?
|
| Inferior Wall Myocardial Infarction | 4 | 2020 | 8 | 1.260 |
Why?
|
| Proto-Oncogene Proteins c-akt | 12 | 2021 | 479 | 1.260 |
Why?
|
| Stroke | 7 | 2021 | 1059 | 1.230 |
Why?
|
| Ventricular Remodeling | 5 | 2020 | 155 | 1.220 |
Why?
|
| Ultrasonic Therapy | 11 | 2007 | 26 | 1.200 |
Why?
|
| Risk Assessment | 20 | 2023 | 3690 | 1.180 |
Why?
|
| Sensitivity and Specificity | 27 | 2026 | 2080 | 1.180 |
Why?
|
| Coronary Thrombosis | 8 | 2020 | 33 | 1.180 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 6 | 2021 | 127 | 1.170 |
Why?
|
| Predictive Value of Tests | 31 | 2025 | 2299 | 1.170 |
Why?
|
| Heart Diseases | 8 | 2025 | 494 | 1.160 |
Why?
|
| Female | 152 | 2025 | 70631 | 1.150 |
Why?
|
| Arrhythmias, Cardiac | 11 | 2023 | 482 | 1.130 |
Why?
|
| Diabetic Nephropathies | 2 | 2021 | 115 | 1.120 |
Why?
|
| Drug Therapy, Combination | 18 | 2024 | 1165 | 1.110 |
Why?
|
| Cardiomyopathy, Hypertrophic | 3 | 2021 | 161 | 1.110 |
Why?
|
| Adrenergic beta-Antagonists | 9 | 2025 | 216 | 1.100 |
Why?
|
| Nitric Oxide Synthase Type II | 8 | 2010 | 91 | 1.100 |
Why?
|
| Prognosis | 44 | 2022 | 4868 | 1.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 3 | 2020 | 214 | 1.070 |
Why?
|
| Ventricular Premature Complexes | 3 | 2017 | 19 | 1.030 |
Why?
|
| Myocytes, Cardiac | 13 | 2020 | 664 | 1.030 |
Why?
|
| Atrial Flutter | 2 | 2020 | 44 | 1.030 |
Why?
|
| Thrombosis | 11 | 2020 | 498 | 1.030 |
Why?
|
| Coronary Artery Bypass | 12 | 2019 | 514 | 1.030 |
Why?
|
| Severity of Illness Index | 17 | 2020 | 3041 | 1.010 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2020 | 133 | 1.010 |
Why?
|
| Ischemic Preconditioning, Myocardial | 4 | 2021 | 13 | 1.000 |
Why?
|
| Practice Guidelines as Topic | 5 | 2020 | 1291 | 0.990 |
Why?
|
| Wolff-Parkinson-White Syndrome | 4 | 2021 | 73 | 0.980 |
Why?
|
| Echocardiography, Stress | 3 | 2019 | 19 | 0.970 |
Why?
|
| Ventricular Septum | 2 | 2023 | 16 | 0.950 |
Why?
|
| Disease Models, Animal | 31 | 2023 | 4663 | 0.950 |
Why?
|
| Apoptosis | 11 | 2020 | 1819 | 0.940 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2025 | 1262 | 0.940 |
Why?
|
| Fibrinolytic Agents | 17 | 2022 | 182 | 0.930 |
Why?
|
| Cardiomyopathies | 3 | 2022 | 514 | 0.890 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 6 | 2012 | 157 | 0.890 |
Why?
|
| Algorithms | 11 | 2021 | 1674 | 0.890 |
Why?
|
| AMP-Activated Protein Kinases | 5 | 2021 | 170 | 0.880 |
Why?
|
| Non-ST Elevated Myocardial Infarction | 1 | 2025 | 20 | 0.880 |
Why?
|
| Vitamin K 2 | 1 | 2024 | 7 | 0.880 |
Why?
|
| Risk Factors | 43 | 2026 | 11020 | 0.880 |
Why?
|
| Diagnostic Errors | 6 | 2014 | 345 | 0.870 |
Why?
|
| Treatment Outcome | 44 | 2025 | 12862 | 0.870 |
Why?
|
| Phosphorylation | 16 | 2020 | 1570 | 0.870 |
Why?
|
| Phosphodiesterase 3 Inhibitors | 3 | 2014 | 8 | 0.870 |
Why?
|
| Hypertrophy, Left Ventricular | 7 | 2020 | 108 | 0.870 |
Why?
|
| Aortic Valve Stenosis | 4 | 2023 | 349 | 0.870 |
Why?
|
| Peptides | 8 | 2016 | 707 | 0.850 |
Why?
|
| Hydrazones | 1 | 2024 | 14 | 0.840 |
Why?
|
| MicroRNAs | 6 | 2019 | 888 | 0.840 |
Why?
|
| Diabetes Mellitus, Experimental | 7 | 2019 | 137 | 0.830 |
Why?
|
| Sodium-Glucose Transporter 2 | 4 | 2023 | 18 | 0.820 |
Why?
|
| Dipeptidyl Peptidase 4 | 3 | 2019 | 22 | 0.820 |
Why?
|
| Hypertension, Pulmonary | 2 | 2020 | 454 | 0.820 |
Why?
|
| Pyridazines | 1 | 2024 | 49 | 0.820 |
Why?
|
| Up-Regulation | 10 | 2018 | 825 | 0.820 |
Why?
|
| Anticholesteremic Agents | 5 | 2019 | 239 | 0.810 |
Why?
|
| Myocardial Revascularization | 6 | 2019 | 100 | 0.810 |
Why?
|
| Vascular Calcification | 1 | 2024 | 70 | 0.810 |
Why?
|
| Hemodynamics | 8 | 2024 | 810 | 0.800 |
Why?
|
| Warfarin | 1 | 2024 | 121 | 0.800 |
Why?
|
| Streptokinase | 14 | 2004 | 18 | 0.780 |
Why?
|
| Gastrointestinal Hemorrhage | 5 | 2025 | 236 | 0.770 |
Why?
|
| PTEN Phosphohydrolase | 6 | 2014 | 252 | 0.760 |
Why?
|
| Eicosanoids | 3 | 2012 | 12 | 0.760 |
Why?
|
| No-Reflow Phenomenon | 2 | 2019 | 8 | 0.760 |
Why?
|
| Venoms | 2 | 2013 | 17 | 0.760 |
Why?
|
| Action Potentials | 4 | 2020 | 472 | 0.750 |
Why?
|
| Incretins | 2 | 2025 | 26 | 0.750 |
Why?
|
| Pericarditis, Constrictive | 1 | 2022 | 6 | 0.750 |
Why?
|
| Syncope | 4 | 2016 | 52 | 0.740 |
Why?
|
| Triazoles | 3 | 2014 | 141 | 0.740 |
Why?
|
| Rosuvastatin Calcium | 3 | 2017 | 42 | 0.740 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2021 | 1607 | 0.740 |
Why?
|
| Time Factors | 33 | 2025 | 6168 | 0.730 |
Why?
|
| Atrioventricular Block | 2 | 2020 | 45 | 0.730 |
Why?
|
| Reproducibility of Results | 17 | 2019 | 2900 | 0.730 |
Why?
|
| Digitalis | 1 | 2021 | 2 | 0.710 |
Why?
|
| Dietary Supplements | 2 | 2024 | 447 | 0.700 |
Why?
|
| Aged, 80 and over | 24 | 2024 | 6773 | 0.700 |
Why?
|
| Vitamin K | 2 | 2024 | 34 | 0.700 |
Why?
|
| Ischemic Postconditioning | 1 | 2021 | 4 | 0.700 |
Why?
|
| Adamantane | 2 | 2018 | 9 | 0.680 |
Why?
|
| Acute Disease | 11 | 2020 | 1152 | 0.680 |
Why?
|
| Insulins | 1 | 2021 | 18 | 0.670 |
Why?
|
| Administration, Oral | 10 | 2025 | 709 | 0.670 |
Why?
|
| Retrospective Studies | 43 | 2025 | 17662 | 0.670 |
Why?
|
| Simvastatin | 4 | 2010 | 76 | 0.660 |
Why?
|
| Dipeptides | 2 | 2018 | 60 | 0.660 |
Why?
|
| Intermittent Claudication | 1 | 2021 | 48 | 0.660 |
Why?
|
| Ischemia | 5 | 2022 | 359 | 0.650 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2011 | 56 | 0.650 |
Why?
|
| Antifibrinolytic Agents | 1 | 2020 | 46 | 0.630 |
Why?
|
| Foreign-Body Migration | 2 | 2018 | 64 | 0.630 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2020 | 32 | 0.620 |
Why?
|
| Patient Admission | 8 | 2007 | 185 | 0.610 |
Why?
|
| Linagliptin | 1 | 2019 | 5 | 0.610 |
Why?
|
| Diabetic Cardiomyopathies | 4 | 2020 | 19 | 0.600 |
Why?
|
| Editorial Policies | 1 | 2020 | 49 | 0.600 |
Why?
|
| Blood Coagulation | 6 | 2002 | 134 | 0.590 |
Why?
|
| Renin-Angiotensin System | 1 | 2020 | 104 | 0.590 |
Why?
|
| Ultrasonography, Interventional | 8 | 2002 | 205 | 0.590 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 197 | 0.580 |
Why?
|
| Data Display | 1 | 2019 | 13 | 0.580 |
Why?
|
| Microcirculation | 1 | 2019 | 104 | 0.580 |
Why?
|
| Sodium-Hydrogen Exchanger 1 | 1 | 2018 | 3 | 0.580 |
Why?
|
| Outpatients | 1 | 2021 | 262 | 0.570 |
Why?
|
| PPAR gamma | 4 | 2017 | 88 | 0.570 |
Why?
|
| Heart Neoplasms | 2 | 2019 | 106 | 0.560 |
Why?
|
| Electric Countershock | 2 | 2017 | 74 | 0.560 |
Why?
|
| Signal Processing, Computer-Assisted | 6 | 2019 | 119 | 0.560 |
Why?
|
| Stroke Volume | 12 | 2025 | 541 | 0.550 |
Why?
|
| Time-to-Treatment | 1 | 2020 | 209 | 0.550 |
Why?
|
| Sulfonamides | 4 | 2014 | 296 | 0.550 |
Why?
|
| Kidney | 4 | 2021 | 1280 | 0.540 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2022 | 3753 | 0.530 |
Why?
|
| Blood Glucose | 9 | 2025 | 1113 | 0.530 |
Why?
|
| Glucagon-Like Peptide 1 | 3 | 2012 | 77 | 0.530 |
Why?
|
| Signal Transduction | 19 | 2020 | 4661 | 0.520 |
Why?
|
| Guideline Adherence | 1 | 2020 | 386 | 0.520 |
Why?
|
| Tachycardia | 1 | 2017 | 66 | 0.520 |
Why?
|
| Cyclic AMP | 3 | 2012 | 220 | 0.520 |
Why?
|
| Pulmonary Heart Disease | 1 | 2017 | 4 | 0.510 |
Why?
|
| Ischemic Preconditioning | 3 | 2019 | 22 | 0.510 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 182 | 0.510 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2017 | 17 | 0.510 |
Why?
|
| Triage | 3 | 2014 | 144 | 0.500 |
Why?
|
| Artifacts | 3 | 2007 | 99 | 0.500 |
Why?
|
| Tissue Plasminogen Activator | 11 | 2004 | 103 | 0.500 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 4 | 2010 | 88 | 0.490 |
Why?
|
| Cyclooxygenase Inhibitors | 5 | 2007 | 47 | 0.480 |
Why?
|
| Cardiomegaly | 1 | 2017 | 117 | 0.480 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2017 | 49 | 0.480 |
Why?
|
| Receptors, Glucagon | 2 | 2013 | 33 | 0.480 |
Why?
|
| Diabetic Angiopathies | 1 | 2016 | 66 | 0.470 |
Why?
|
| Mice | 18 | 2023 | 18209 | 0.470 |
Why?
|
| Aneurysm, False | 3 | 2006 | 84 | 0.470 |
Why?
|
| Angina, Unstable | 4 | 2006 | 49 | 0.460 |
Why?
|
| Anti-Inflammatory Agents | 3 | 2021 | 298 | 0.460 |
Why?
|
| Adult | 48 | 2022 | 31146 | 0.460 |
Why?
|
| Cardiac Catheterization | 6 | 2018 | 629 | 0.450 |
Why?
|
| Immunoblotting | 6 | 2012 | 292 | 0.450 |
Why?
|
| Dyspnea | 3 | 2013 | 159 | 0.450 |
Why?
|
| Sick Sinus Syndrome | 2 | 2014 | 17 | 0.450 |
Why?
|
| Clinical Trials as Topic | 4 | 2018 | 1123 | 0.450 |
Why?
|
| Coronary Vasospasm | 2 | 2014 | 12 | 0.450 |
Why?
|
| Fibroblasts | 2 | 2018 | 849 | 0.450 |
Why?
|
| Heart Aneurysm | 3 | 2011 | 27 | 0.440 |
Why?
|
| Drug Interactions | 7 | 2024 | 236 | 0.440 |
Why?
|
| Atrial Premature Complexes | 1 | 2014 | 1 | 0.430 |
Why?
|
| Fluorobenzenes | 1 | 2014 | 39 | 0.420 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 3 | 2014 | 42 | 0.420 |
Why?
|
| Phospholipases A2, Cytosolic | 2 | 2011 | 2 | 0.410 |
Why?
|
| Diabetes Complications | 3 | 2014 | 197 | 0.410 |
Why?
|
| Sinoatrial Block | 1 | 2013 | 1 | 0.410 |
Why?
|
| Postoperative Complications | 7 | 2019 | 3130 | 0.410 |
Why?
|
| Hydroxyethyl Starch Derivatives | 3 | 2003 | 8 | 0.400 |
Why?
|
| Biomedical Research | 1 | 2020 | 561 | 0.400 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 79 | 0.400 |
Why?
|
| Stents | 7 | 2018 | 793 | 0.390 |
Why?
|
| Hospital Mortality | 11 | 2022 | 1062 | 0.390 |
Why?
|
| Enzyme Activation | 5 | 2020 | 576 | 0.390 |
Why?
|
| Drug Discovery | 1 | 2015 | 176 | 0.390 |
Why?
|
| Technetium Tc 99m Sestamibi | 7 | 2005 | 23 | 0.390 |
Why?
|
| Heart Block | 3 | 2016 | 37 | 0.380 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 5 | 2014 | 7 | 0.380 |
Why?
|
| Gene Expression Regulation | 7 | 2023 | 2320 | 0.380 |
Why?
|
| Arachidonate 5-Lipoxygenase | 2 | 2012 | 4 | 0.380 |
Why?
|
| Diastole | 3 | 2024 | 181 | 0.370 |
Why?
|
| NF-kappa B | 2 | 2020 | 440 | 0.370 |
Why?
|
| Nitric Oxide Synthase | 3 | 2008 | 170 | 0.370 |
Why?
|
| Accidental Falls | 1 | 2013 | 112 | 0.360 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2013 | 128 | 0.360 |
Why?
|
| Mice, Inbred C57BL | 11 | 2021 | 4700 | 0.360 |
Why?
|
| Decision Making, Computer-Assisted | 2 | 2011 | 19 | 0.360 |
Why?
|
| Ventricular Septal Rupture | 2 | 2002 | 4 | 0.350 |
Why?
|
| Fumarates | 1 | 2011 | 18 | 0.350 |
Why?
|
| Recovery of Function | 2 | 2013 | 448 | 0.350 |
Why?
|
| Bradycardia | 3 | 2016 | 58 | 0.350 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2011 | 49 | 0.350 |
Why?
|
| Death, Sudden, Cardiac | 3 | 2007 | 268 | 0.350 |
Why?
|
| Lipopolysaccharides | 2 | 2018 | 298 | 0.350 |
Why?
|
| Coronary Vessel Anomalies | 2 | 2006 | 279 | 0.350 |
Why?
|
| Diabetes Mellitus | 4 | 2014 | 888 | 0.340 |
Why?
|
| Amides | 1 | 2011 | 81 | 0.340 |
Why?
|
| Fibrosis | 6 | 2020 | 424 | 0.340 |
Why?
|
| Phosphodiesterase Inhibitors | 4 | 2007 | 54 | 0.340 |
Why?
|
| Valine | 1 | 2011 | 110 | 0.340 |
Why?
|
| Glyburide | 2 | 2008 | 22 | 0.340 |
Why?
|
| Pyrimidines | 1 | 2014 | 446 | 0.330 |
Why?
|
| Hyperlipidemias | 2 | 2012 | 185 | 0.330 |
Why?
|
| Heparin | 6 | 2003 | 206 | 0.330 |
Why?
|
| Glucagon-Like Peptide-1 Receptor | 3 | 2018 | 44 | 0.320 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2011 | 77 | 0.320 |
Why?
|
| Proton Pump Inhibitors | 2 | 2024 | 275 | 0.320 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 3 | 2008 | 60 | 0.310 |
Why?
|
| Incidence | 11 | 2025 | 3336 | 0.310 |
Why?
|
| Rabbits | 11 | 2007 | 573 | 0.310 |
Why?
|
| Torsades de Pointes | 1 | 2010 | 8 | 0.310 |
Why?
|
| Ofloxacin | 1 | 2010 | 29 | 0.310 |
Why?
|
| Drug Synergism | 5 | 2016 | 236 | 0.310 |
Why?
|
| Arteriosclerosis | 3 | 2004 | 109 | 0.310 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 978 | 0.310 |
Why?
|
| Atherosclerosis | 4 | 2022 | 947 | 0.300 |
Why?
|
| Levofloxacin | 1 | 2010 | 49 | 0.300 |
Why?
|
| Reperfusion Injury | 2 | 2007 | 107 | 0.300 |
Why?
|
| Pyrazines | 1 | 2010 | 78 | 0.300 |
Why?
|
| Insulin Resistance | 1 | 2014 | 686 | 0.300 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2010 | 82 | 0.300 |
Why?
|
| Leukotriene B4 | 1 | 2008 | 6 | 0.280 |
Why?
|
| Aortic Valve | 5 | 2023 | 455 | 0.280 |
Why?
|
| Sulfonylurea Compounds | 1 | 2008 | 20 | 0.280 |
Why?
|
| Endothelium, Vascular | 3 | 2007 | 468 | 0.280 |
Why?
|
| Food-Drug Interactions | 1 | 2008 | 10 | 0.270 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 1369 | 0.270 |
Why?
|
| Transcatheter Aortic Valve Replacement | 2 | 2021 | 227 | 0.270 |
Why?
|
| Recurrence | 10 | 2013 | 1484 | 0.270 |
Why?
|
| Coffee | 1 | 2008 | 28 | 0.270 |
Why?
|
| Logistic Models | 14 | 2020 | 1796 | 0.270 |
Why?
|
| Prasugrel Hydrochloride | 2 | 2019 | 23 | 0.270 |
Why?
|
| Azetidines | 1 | 2008 | 60 | 0.270 |
Why?
|
| Caffeine | 1 | 2008 | 65 | 0.260 |
Why?
|
| Collateral Circulation | 4 | 2005 | 42 | 0.260 |
Why?
|
| Prostaglandin D2 | 1 | 2007 | 4 | 0.260 |
Why?
|
| Myocardial Stunning | 3 | 1996 | 17 | 0.260 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2019 | 2062 | 0.250 |
Why?
|
| Prospective Studies | 17 | 2022 | 6432 | 0.250 |
Why?
|
| Clinical Competence | 1 | 2014 | 1046 | 0.250 |
Why?
|
| Dyslipidemias | 1 | 2010 | 253 | 0.250 |
Why?
|
| Pericardial Effusion | 3 | 2005 | 78 | 0.250 |
Why?
|
| CARD Signaling Adaptor Proteins | 2 | 2017 | 42 | 0.250 |
Why?
|
| Oxazoles | 2 | 2017 | 21 | 0.250 |
Why?
|
| Hospitalization | 8 | 2025 | 1946 | 0.240 |
Why?
|
| PPAR alpha | 2 | 2017 | 54 | 0.240 |
Why?
|
| Piperazines | 2 | 2006 | 263 | 0.240 |
Why?
|
| Heart Transplantation | 1 | 2013 | 799 | 0.240 |
Why?
|
| Thiophenes | 2 | 2017 | 69 | 0.240 |
Why?
|
| Pyrrolidines | 1 | 2006 | 49 | 0.240 |
Why?
|
| Clinical Decision-Making | 2 | 2019 | 314 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 3 | 2010 | 106 | 0.230 |
Why?
|
| Insulin | 2 | 2025 | 1145 | 0.230 |
Why?
|
| Societies, Medical | 3 | 2020 | 793 | 0.230 |
Why?
|
| Femoral Artery | 4 | 2007 | 134 | 0.230 |
Why?
|
| Cells, Cultured | 9 | 2018 | 2884 | 0.230 |
Why?
|
| Pericardium | 2 | 2022 | 103 | 0.220 |
Why?
|
| Glucose | 2 | 2021 | 851 | 0.220 |
Why?
|
| Accidents, Traffic | 1 | 2006 | 102 | 0.220 |
Why?
|
| Waiting Lists | 1 | 2007 | 249 | 0.220 |
Why?
|
| Prostaglandins | 1 | 2005 | 35 | 0.220 |
Why?
|
| Munchausen Syndrome | 1 | 2004 | 2 | 0.220 |
Why?
|
| Ticlopidine | 2 | 2015 | 28 | 0.220 |
Why?
|
| Tyrosine | 3 | 2011 | 142 | 0.220 |
Why?
|
| Pericardiocentesis | 2 | 2005 | 17 | 0.220 |
Why?
|
| Hypotension, Orthostatic | 1 | 2004 | 20 | 0.220 |
Why?
|
| Aortic Coarctation | 1 | 2006 | 98 | 0.210 |
Why?
|
| Surgical Procedures, Operative | 1 | 2007 | 225 | 0.210 |
Why?
|
| Gastroparesis | 1 | 2005 | 68 | 0.210 |
Why?
|
| Aortic Rupture | 1 | 2006 | 112 | 0.210 |
Why?
|
| Electric Stimulation Therapy | 1 | 2005 | 90 | 0.210 |
Why?
|
| Intraoperative Complications | 1 | 2006 | 153 | 0.210 |
Why?
|
| Heart Failure, Diastolic | 1 | 2024 | 10 | 0.210 |
Why?
|
| Heart Valve Prosthesis | 4 | 2004 | 303 | 0.210 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 6 | 2005 | 96 | 0.210 |
Why?
|
| Body Weight | 6 | 2012 | 985 | 0.210 |
Why?
|
| Cause of Death | 3 | 2018 | 502 | 0.210 |
Why?
|
| Creatinine | 3 | 2021 | 398 | 0.210 |
Why?
|
| Analysis of Variance | 7 | 2007 | 927 | 0.210 |
Why?
|
| Vasodilator Agents | 2 | 2021 | 197 | 0.210 |
Why?
|
| Patient Discharge | 3 | 2006 | 514 | 0.210 |
Why?
|
| Albumins | 2 | 2021 | 87 | 0.200 |
Why?
|
| Tetralogy of Fallot | 1 | 2006 | 170 | 0.200 |
Why?
|
| Takotsubo Cardiomyopathy | 2 | 2015 | 14 | 0.200 |
Why?
|
| Heart Rupture, Post-Infarction | 1 | 2003 | 7 | 0.200 |
Why?
|
| Necrosis | 5 | 2006 | 192 | 0.200 |
Why?
|
| Blood | 2 | 2001 | 98 | 0.200 |
Why?
|
| Radiopharmaceuticals | 5 | 2005 | 152 | 0.190 |
Why?
|
| Bundle of His | 2 | 2022 | 17 | 0.190 |
Why?
|
| Phospholipases A2 | 3 | 2010 | 31 | 0.190 |
Why?
|
| Protective Agents | 2 | 2016 | 33 | 0.190 |
Why?
|
| Hindlimb | 2 | 2007 | 72 | 0.190 |
Why?
|
| Hernia, Hiatal | 1 | 2003 | 55 | 0.190 |
Why?
|
| Potassium Channels | 1 | 2004 | 154 | 0.190 |
Why?
|
| In Vitro Techniques | 7 | 2013 | 808 | 0.190 |
Why?
|
| Mice, Knockout | 7 | 2017 | 3818 | 0.190 |
Why?
|
| Emergency Service, Hospital | 2 | 2023 | 1221 | 0.190 |
Why?
|
| Echocardiography, Doppler, Color | 3 | 2004 | 113 | 0.190 |
Why?
|
| Health Status Disparities | 1 | 2026 | 282 | 0.190 |
Why?
|
| Inflammation Mediators | 3 | 2020 | 226 | 0.190 |
Why?
|
| Drug Administration Schedule | 5 | 2021 | 723 | 0.190 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2004 | 194 | 0.190 |
Why?
|
| Health Care Costs | 1 | 2026 | 407 | 0.190 |
Why?
|
| Follow-Up Studies | 10 | 2013 | 5184 | 0.190 |
Why?
|
| Pulmonary Artery | 2 | 1999 | 434 | 0.190 |
Why?
|
| Patients | 1 | 2023 | 122 | 0.180 |
Why?
|
| Cholesterol, LDL | 2 | 2019 | 604 | 0.180 |
Why?
|
| Aorta | 1 | 2006 | 521 | 0.180 |
Why?
|
| Antacids | 1 | 2022 | 28 | 0.180 |
Why?
|
| Morphine Derivatives | 1 | 2022 | 5 | 0.180 |
Why?
|
| Circulating MicroRNA | 2 | 2019 | 12 | 0.180 |
Why?
|
| Histamine H2 Antagonists | 1 | 2022 | 47 | 0.180 |
Why?
|
| Apyrase | 1 | 2022 | 22 | 0.180 |
Why?
|
| Pyrazoles | 3 | 2024 | 349 | 0.180 |
Why?
|
| Ketosis | 1 | 2021 | 14 | 0.170 |
Why?
|
| Digoxin | 1 | 2021 | 37 | 0.170 |
Why?
|
| Hematoxylin | 1 | 2021 | 8 | 0.170 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2021 | 9 | 0.170 |
Why?
|
| Periodic Acid | 1 | 2021 | 5 | 0.170 |
Why?
|
| Ultrasonics | 1 | 2001 | 31 | 0.170 |
Why?
|
| Fibrinolysis | 1 | 2001 | 44 | 0.170 |
Why?
|
| Electrodes, Implanted | 1 | 2002 | 180 | 0.170 |
Why?
|
| Heart Rupture | 1 | 2001 | 4 | 0.170 |
Why?
|
| Terminology as Topic | 2 | 2017 | 226 | 0.170 |
Why?
|
| Pulmonary Embolism | 1 | 2003 | 182 | 0.170 |
Why?
|
| Hypertension | 5 | 2018 | 1353 | 0.170 |
Why?
|
| Enzyme Induction | 2 | 2014 | 92 | 0.170 |
Why?
|
| Disease Progression | 6 | 2020 | 2195 | 0.170 |
Why?
|
| Cystatin C | 1 | 2021 | 70 | 0.160 |
Why?
|
| Isoquinolines | 2 | 2012 | 43 | 0.160 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2020 | 45 | 0.160 |
Why?
|
| Gadolinium | 2 | 2018 | 110 | 0.160 |
Why?
|
| Healthcare Disparities | 1 | 2026 | 520 | 0.160 |
Why?
|
| Electroacupuncture | 1 | 2020 | 8 | 0.160 |
Why?
|
| Syndrome | 4 | 2007 | 1155 | 0.160 |
Why?
|
| Aortic Aneurysm | 1 | 2003 | 224 | 0.160 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2021 | 80 | 0.160 |
Why?
|
| Muscle, Skeletal | 3 | 2014 | 981 | 0.160 |
Why?
|
| Odds Ratio | 7 | 2020 | 1209 | 0.160 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2002 | 178 | 0.160 |
Why?
|
| Therapeutic Equivalency | 1 | 2020 | 15 | 0.160 |
Why?
|
| Survival Rate | 7 | 2018 | 2111 | 0.160 |
Why?
|
| Dobutamine | 2 | 2019 | 48 | 0.160 |
Why?
|
| bcl-2-Associated X Protein | 2 | 2010 | 64 | 0.160 |
Why?
|
| Sonication | 1 | 1999 | 7 | 0.160 |
Why?
|
| Secondary Prevention | 3 | 2019 | 216 | 0.160 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2020 | 157 | 0.150 |
Why?
|
| Journal Impact Factor | 1 | 2020 | 26 | 0.150 |
Why?
|
| Inflammation | 3 | 2022 | 1481 | 0.150 |
Why?
|
| Abnormalities, Multiple | 1 | 2006 | 963 | 0.150 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2019 | 45 | 0.150 |
Why?
|
| Cohort Studies | 6 | 2018 | 5049 | 0.150 |
Why?
|
| Down-Regulation | 2 | 2018 | 645 | 0.150 |
Why?
|
| Smoking | 3 | 2007 | 930 | 0.150 |
Why?
|
| Fibrin | 1 | 1999 | 64 | 0.150 |
Why?
|
| Diabetic Ketoacidosis | 1 | 2021 | 169 | 0.150 |
Why?
|
| Diabetes Mellitus, Type 1 | 2 | 2021 | 893 | 0.150 |
Why?
|
| Blotting, Western | 2 | 2012 | 1013 | 0.150 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2015 | 227 | 0.150 |
Why?
|
| Arterio-Arterial Fistula | 1 | 1999 | 10 | 0.150 |
Why?
|
| Swine | 3 | 2018 | 1182 | 0.150 |
Why?
|
| Shock, Cardiogenic | 4 | 2020 | 176 | 0.150 |
Why?
|
| Injections, Intravenous | 2 | 2010 | 238 | 0.150 |
Why?
|
| RNA, Messenger | 3 | 2016 | 2544 | 0.140 |
Why?
|
| Angina Pectoris | 3 | 1996 | 56 | 0.140 |
Why?
|
| Endoglin | 1 | 2019 | 30 | 0.140 |
Why?
|
| Cyclooxygenase 1 | 2 | 2010 | 21 | 0.140 |
Why?
|
| Nitric Oxide Synthase Type I | 2 | 2010 | 28 | 0.140 |
Why?
|
| Blood Pressure | 5 | 2013 | 1345 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2019 | 61 | 0.140 |
Why?
|
| Asymptomatic Diseases | 1 | 2019 | 77 | 0.140 |
Why?
|
| Multimorbidity | 1 | 2018 | 23 | 0.140 |
Why?
|
| Aorta, Thoracic | 1 | 2003 | 526 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2022 | 485 | 0.140 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2018 | 72 | 0.140 |
Why?
|
| Erythrocytes | 1 | 2019 | 186 | 0.140 |
Why?
|
| Energy Metabolism | 1 | 2023 | 803 | 0.140 |
Why?
|
| Cardiomyopathy, Alcoholic | 1 | 2018 | 4 | 0.140 |
Why?
|
| Statistics as Topic | 3 | 2004 | 241 | 0.140 |
Why?
|
| Receptors, Opioid, delta | 2 | 2009 | 12 | 0.140 |
Why?
|
| Radiographic Image Enhancement | 1 | 2018 | 38 | 0.140 |
Why?
|
| Membrane Proteins | 3 | 2012 | 1590 | 0.140 |
Why?
|
| Receptors, Adrenergic, beta-2 | 2 | 2009 | 57 | 0.140 |
Why?
|
| Dexmedetomidine | 1 | 2018 | 46 | 0.140 |
Why?
|
| Echocardiography, Transesophageal | 4 | 2006 | 246 | 0.140 |
Why?
|
| Administration, Intravenous | 1 | 2018 | 172 | 0.140 |
Why?
|
| Extracellular Vesicles | 1 | 2019 | 76 | 0.130 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2020 | 428 | 0.130 |
Why?
|
| Receptors, Purinergic P1 | 2 | 2008 | 12 | 0.130 |
Why?
|
| Troponin | 1 | 2018 | 69 | 0.130 |
Why?
|
| Anti-Bacterial Agents | 1 | 2010 | 2580 | 0.130 |
Why?
|
| Models, Cardiovascular | 3 | 2010 | 165 | 0.130 |
Why?
|
| Combined Modality Therapy | 7 | 2003 | 1211 | 0.130 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 2 | 2010 | 63 | 0.130 |
Why?
|
| Serum Albumin | 1 | 1998 | 101 | 0.130 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2017 | 29 | 0.130 |
Why?
|
| Iliac Artery | 1 | 1998 | 63 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2013 | 617 | 0.130 |
Why?
|
| L-Selectin | 1 | 1997 | 18 | 0.130 |
Why?
|
| Radiography, Thoracic | 1 | 2018 | 144 | 0.130 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2018 | 83 | 0.130 |
Why?
|
| E-Selectin | 1 | 1997 | 38 | 0.130 |
Why?
|
| Riots | 1 | 1997 | 2 | 0.130 |
Why?
|
| Hypnotics and Sedatives | 1 | 2018 | 131 | 0.130 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 365 | 0.130 |
Why?
|
| Arabs | 1 | 1997 | 29 | 0.130 |
Why?
|
| P-Selectin | 1 | 1997 | 69 | 0.130 |
Why?
|
| Radiography | 5 | 2006 | 741 | 0.130 |
Why?
|
| Cardiovascular System | 1 | 2018 | 96 | 0.130 |
Why?
|
| Infarction | 1 | 1997 | 20 | 0.130 |
Why?
|
| Equipment Design | 1 | 2019 | 509 | 0.130 |
Why?
|
| Oligosaccharides | 1 | 1997 | 71 | 0.130 |
Why?
|
| Pattern Recognition, Automated | 2 | 2013 | 40 | 0.130 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2018 | 176 | 0.130 |
Why?
|
| Rats, Zucker | 1 | 2016 | 25 | 0.130 |
Why?
|
| Glucagon-Like Peptide-2 Receptor | 1 | 2016 | 13 | 0.120 |
Why?
|
| Intramolecular Oxidoreductases | 2 | 2008 | 41 | 0.120 |
Why?
|
| Ubiquinone | 1 | 1996 | 23 | 0.120 |
Why?
|
| Comorbidity | 2 | 2018 | 1589 | 0.120 |
Why?
|
| Gangliosides | 1 | 1997 | 72 | 0.120 |
Why?
|
| Liraglutide | 1 | 2016 | 15 | 0.120 |
Why?
|
| Israel | 4 | 2002 | 44 | 0.120 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2017 | 74 | 0.120 |
Why?
|
| Blood Platelets | 1 | 2019 | 313 | 0.120 |
Why?
|
| Arteries | 1 | 1997 | 208 | 0.120 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2008 | 104 | 0.120 |
Why?
|
| Staining and Labeling | 1 | 1997 | 166 | 0.120 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 645 | 0.120 |
Why?
|
| Interleukin-1beta | 1 | 2016 | 156 | 0.120 |
Why?
|
| Violence | 1 | 1997 | 129 | 0.120 |
Why?
|
| Acute Kidney Injury | 2 | 1994 | 705 | 0.120 |
Why?
|
| Nicotinic Agonists | 1 | 1996 | 33 | 0.120 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 713 | 0.120 |
Why?
|
| Observer Variation | 3 | 2014 | 311 | 0.120 |
Why?
|
| Cell Survival | 3 | 2017 | 824 | 0.120 |
Why?
|
| Pleasure | 1 | 2015 | 10 | 0.120 |
Why?
|
| Coitus | 1 | 2015 | 21 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2008 | 787 | 0.120 |
Why?
|
| Phospholipases A | 2 | 2006 | 31 | 0.110 |
Why?
|
| Chi-Square Distribution | 5 | 2011 | 562 | 0.110 |
Why?
|
| Rest | 1 | 2015 | 64 | 0.110 |
Why?
|
| RNA Interference | 2 | 2017 | 491 | 0.110 |
Why?
|
| United States | 7 | 2022 | 12030 | 0.110 |
Why?
|
| Injections, Intraperitoneal | 1 | 2015 | 65 | 0.110 |
Why?
|
| Risk | 1 | 2017 | 723 | 0.110 |
Why?
|
| Texas | 4 | 2013 | 3663 | 0.110 |
Why?
|
| Nicotine | 1 | 1996 | 115 | 0.110 |
Why?
|
| Models, Biological | 2 | 2012 | 1371 | 0.110 |
Why?
|
| Multivariate Analysis | 8 | 2007 | 1376 | 0.110 |
Why?
|
| Contrast Media | 4 | 2017 | 474 | 0.110 |
Why?
|
| Creatine Kinase, MB Form | 2 | 2012 | 21 | 0.110 |
Why?
|
| Caspase 3 | 2 | 2017 | 121 | 0.110 |
Why?
|
| Random Allocation | 3 | 2005 | 409 | 0.110 |
Why?
|
| RNA | 1 | 2018 | 514 | 0.110 |
Why?
|
| Interleukin-6 | 1 | 2016 | 411 | 0.110 |
Why?
|
| Preoperative Care | 3 | 2012 | 356 | 0.110 |
Why?
|
| Angina Pectoris, Variant | 1 | 2014 | 3 | 0.110 |
Why?
|
| Parkinson Disease | 1 | 2002 | 733 | 0.110 |
Why?
|
| Diet, Western | 1 | 2014 | 20 | 0.110 |
Why?
|
| Immune Complex Diseases | 1 | 1994 | 6 | 0.110 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 1590 | 0.110 |
Why?
|
| Hyperglycemia | 1 | 2017 | 233 | 0.110 |
Why?
|
| Protein Binding | 1 | 2018 | 1649 | 0.110 |
Why?
|
| Receptor, Adenosine A1 | 1 | 2014 | 2 | 0.110 |
Why?
|
| Adenosine A1 Receptor Antagonists | 1 | 2014 | 3 | 0.110 |
Why?
|
| Adenosine A2 Receptor Antagonists | 1 | 2014 | 11 | 0.110 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2014 | 11 | 0.110 |
Why?
|
| Echocardiography, Doppler | 4 | 2005 | 158 | 0.110 |
Why?
|
| Ultrasonography | 4 | 2001 | 942 | 0.110 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 148 | 0.100 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2013 | 425 | 0.100 |
Why?
|
| Stem Cells | 1 | 2019 | 702 | 0.100 |
Why?
|
| Age Factors | 5 | 2024 | 2818 | 0.100 |
Why?
|
| Ezetimibe | 2 | 2019 | 93 | 0.100 |
Why?
|
| Regression Analysis | 4 | 2005 | 760 | 0.100 |
Why?
|
| Organ Size | 2 | 2010 | 407 | 0.100 |
Why?
|
| Calcium | 2 | 2010 | 1008 | 0.100 |
Why?
|
| Hemarthrosis | 1 | 1993 | 4 | 0.100 |
Why?
|
| Congresses as Topic | 2 | 2019 | 183 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2014 | 378 | 0.100 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2012 | 124 | 0.100 |
Why?
|
| Quinazolines | 1 | 2014 | 176 | 0.100 |
Why?
|
| Survival Analysis | 4 | 2018 | 1480 | 0.100 |
Why?
|
| Benzopyrans | 1 | 2013 | 19 | 0.100 |
Why?
|
| Tachycardia, Sinus | 1 | 2013 | 6 | 0.100 |
Why?
|
| Stellate Ganglion | 1 | 2013 | 8 | 0.100 |
Why?
|
| Ethanolamines | 1 | 2013 | 24 | 0.100 |
Why?
|
| Atenolol | 1 | 2013 | 43 | 0.100 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 90 | 0.100 |
Why?
|
| Aortic Aneurysm, Thoracic | 2 | 1999 | 699 | 0.100 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 1992 | 22 | 0.090 |
Why?
|
| Metabolic Syndrome | 1 | 2016 | 367 | 0.090 |
Why?
|
| Diuretics | 1 | 2013 | 159 | 0.090 |
Why?
|
| Cardiology | 2 | 2016 | 513 | 0.090 |
Why?
|
| Mammary Arteries | 1 | 1992 | 30 | 0.090 |
Why?
|
| Diabetic Retinopathy | 1 | 2013 | 75 | 0.090 |
Why?
|
| Genetic Pleiotropy | 1 | 2012 | 25 | 0.090 |
Why?
|
| Microspheres | 2 | 2003 | 66 | 0.090 |
Why?
|
| Prevalence | 5 | 2011 | 2693 | 0.090 |
Why?
|
| Chromosomes, Mammalian | 1 | 2012 | 40 | 0.090 |
Why?
|
| Arteriovenous Fistula | 1 | 1992 | 54 | 0.090 |
Why?
|
| Anesthetics, Local | 1 | 2013 | 83 | 0.090 |
Why?
|
| Double-Blind Method | 4 | 2018 | 1613 | 0.090 |
Why?
|
| Dogs | 4 | 2003 | 613 | 0.090 |
Why?
|
| Valsartan | 1 | 2011 | 24 | 0.090 |
Why?
|
| Emergency Medical Services | 2 | 2014 | 352 | 0.090 |
Why?
|
| Brugada Syndrome | 1 | 2011 | 8 | 0.090 |
Why?
|
| Nerve Block | 1 | 2013 | 69 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 324 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2013 | 288 | 0.090 |
Why?
|
| Biomarkers | 6 | 2020 | 3371 | 0.090 |
Why?
|
| Mice, Inbred Strains | 1 | 2011 | 263 | 0.090 |
Why?
|
| Radionuclide Imaging | 3 | 2005 | 113 | 0.090 |
Why?
|
| Kidney Failure, Chronic | 3 | 2020 | 933 | 0.080 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 2 | 2002 | 25 | 0.080 |
Why?
|
| Transcriptome | 1 | 2018 | 1098 | 0.080 |
Why?
|
| Chronic Disease | 3 | 2022 | 1244 | 0.080 |
Why?
|
| Emergencies | 1 | 2012 | 171 | 0.080 |
Why?
|
| Troponin I | 1 | 2012 | 121 | 0.080 |
Why?
|
| Polygeline | 2 | 2001 | 2 | 0.080 |
Why?
|
| Plasma Substitutes | 2 | 2001 | 7 | 0.080 |
Why?
|
| CREB-Binding Protein | 1 | 2010 | 54 | 0.080 |
Why?
|
| Sitagliptin Phosphate | 1 | 2010 | 9 | 0.080 |
Why?
|
| Retina | 1 | 2013 | 423 | 0.080 |
Why?
|
| Veterans | 1 | 2022 | 1756 | 0.080 |
Why?
|
| Hypoxia | 1 | 2012 | 247 | 0.080 |
Why?
|
| Cell Hypoxia | 1 | 2010 | 85 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2013 | 414 | 0.080 |
Why?
|
| Triglycerides | 1 | 2012 | 602 | 0.080 |
Why?
|
| Sex Factors | 4 | 2020 | 1348 | 0.080 |
Why?
|
| Cholesterol | 1 | 2012 | 538 | 0.080 |
Why?
|
| Myocardial Contraction | 4 | 2009 | 241 | 0.080 |
Why?
|
| Culture Media | 1 | 2010 | 169 | 0.080 |
Why?
|
| Receptors, Calcitonin Gene-Related Peptide | 1 | 2009 | 20 | 0.070 |
Why?
|
| Exercise Test | 3 | 2025 | 239 | 0.070 |
Why?
|
| Cell Line | 2 | 2013 | 2550 | 0.070 |
Why?
|
| Sodium Chloride | 2 | 1999 | 89 | 0.070 |
Why?
|
| Models, Animal | 2 | 2012 | 449 | 0.070 |
Why?
|
| Lipids | 1 | 2012 | 566 | 0.070 |
Why?
|
| Calcium Channel Blockers | 2 | 2022 | 107 | 0.070 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 382 | 0.070 |
Why?
|
| Decanoic Acids | 1 | 2008 | 4 | 0.070 |
Why?
|
| Hydroxy Acids | 1 | 2008 | 3 | 0.070 |
Why?
|
| KATP Channels | 1 | 2008 | 11 | 0.070 |
Why?
|
| Calcitonin Gene-Related Peptide | 1 | 2009 | 85 | 0.070 |
Why?
|
| ErbB Receptors | 1 | 2010 | 285 | 0.070 |
Why?
|
| Nervous System Diseases | 1 | 2012 | 394 | 0.070 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2008 | 52 | 0.070 |
Why?
|
| Tyrphostins | 1 | 2008 | 13 | 0.070 |
Why?
|
| Ligation | 1 | 2008 | 134 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1205 | 0.070 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2008 | 52 | 0.070 |
Why?
|
| Myocarditis | 1 | 1989 | 122 | 0.070 |
Why?
|
| Drug Combinations | 2 | 2007 | 267 | 0.070 |
Why?
|
| Multicenter Studies as Topic | 2 | 2007 | 293 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 334 | 0.070 |
Why?
|
| Propranolol | 1 | 2008 | 110 | 0.070 |
Why?
|
| Fluorocarbons | 2 | 1999 | 66 | 0.070 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2006 | 61 | 0.070 |
Why?
|
| Mitochondria, Heart | 1 | 2008 | 58 | 0.070 |
Why?
|
| Angioplasty, Balloon | 2 | 2011 | 122 | 0.070 |
Why?
|
| Janus Kinases | 1 | 2008 | 36 | 0.070 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2006 | 161 | 0.070 |
Why?
|
| Sildenafil Citrate | 2 | 2006 | 56 | 0.070 |
Why?
|
| Sulfones | 2 | 2006 | 72 | 0.070 |
Why?
|
| Serine | 1 | 2008 | 161 | 0.070 |
Why?
|
| Theophylline | 1 | 2007 | 23 | 0.070 |
Why?
|
| Creatine Kinase, BB Form | 1 | 2007 | 4 | 0.070 |
Why?
|
| Survival | 1 | 2007 | 16 | 0.070 |
Why?
|
| Purines | 2 | 2006 | 117 | 0.070 |
Why?
|
| Butadienes | 1 | 2007 | 22 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 225 | 0.070 |
Why?
|
| 5'-Nucleotidase | 1 | 2007 | 24 | 0.060 |
Why?
|
| Brachial Artery | 1 | 2007 | 34 | 0.060 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 140 | 0.060 |
Why?
|
| Creatine Kinase | 2 | 1998 | 61 | 0.060 |
Why?
|
| CD36 Antigens | 1 | 2007 | 35 | 0.060 |
Why?
|
| Models, Chemical | 1 | 2007 | 78 | 0.060 |
Why?
|
| Colitis, Ulcerative | 1 | 1989 | 210 | 0.060 |
Why?
|
| Nitroso Compounds | 1 | 2006 | 7 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2008 | 190 | 0.060 |
Why?
|
| Biotin | 1 | 2006 | 39 | 0.060 |
Why?
|
| Nitriles | 1 | 2007 | 162 | 0.060 |
Why?
|
| Constriction, Pathologic | 3 | 1997 | 221 | 0.060 |
Why?
|
| Gene Expression | 1 | 2011 | 1481 | 0.060 |
Why?
|
| Inositol Polyphosphate 5-Phosphatases | 1 | 2006 | 6 | 0.060 |
Why?
|
| Amidines | 1 | 2006 | 1 | 0.060 |
Why?
|
| Oncogene Protein v-akt | 1 | 2006 | 32 | 0.060 |
Why?
|
| Benzylamines | 1 | 2006 | 22 | 0.060 |
Why?
|
| Hypercalcemia | 1 | 2006 | 41 | 0.060 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2006 | 97 | 0.060 |
Why?
|
| Feasibility Studies | 2 | 1999 | 822 | 0.060 |
Why?
|
| Forecasting | 2 | 2005 | 351 | 0.060 |
Why?
|
| Alanine | 1 | 2006 | 160 | 0.060 |
Why?
|
| Prostaglandin-E Synthases | 1 | 2005 | 7 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2008 | 1445 | 0.060 |
Why?
|
| Isoxazoles | 1 | 2005 | 32 | 0.050 |
Why?
|
| Obesity | 1 | 2016 | 2416 | 0.050 |
Why?
|
| Regional Blood Flow | 3 | 2007 | 191 | 0.050 |
Why?
|
| Reference Values | 2 | 2003 | 673 | 0.050 |
Why?
|
| Exercise | 2 | 2005 | 892 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 290 | 0.050 |
Why?
|
| Pilot Projects | 3 | 2013 | 1441 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 1 | 2004 | 126 | 0.050 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 558 | 0.050 |
Why?
|
| Polyethylene Terephthalates | 1 | 2004 | 22 | 0.050 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2013 | 852 | 0.050 |
Why?
|
| Statistics, Nonparametric | 2 | 2018 | 421 | 0.050 |
Why?
|
| Mitral Valve | 2 | 2004 | 245 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2007 | 469 | 0.050 |
Why?
|
| Brachiocephalic Trunk | 1 | 2004 | 35 | 0.050 |
Why?
|
| Postoperative Period | 2 | 2012 | 331 | 0.050 |
Why?
|
| Blood Flow Velocity | 3 | 2005 | 417 | 0.050 |
Why?
|
| Social Determinants of Health | 1 | 2026 | 165 | 0.050 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2004 | 80 | 0.050 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2004 | 59 | 0.050 |
Why?
|
| Swine Diseases | 1 | 2004 | 42 | 0.050 |
Why?
|
| Pneumonia | 2 | 2020 | 340 | 0.050 |
Why?
|
| Pyridones | 1 | 2024 | 139 | 0.050 |
Why?
|
| Blood Vessel Prosthesis Implantation | 2 | 2004 | 761 | 0.050 |
Why?
|
| Prosthesis Failure | 2 | 2004 | 158 | 0.050 |
Why?
|
| Dilatation, Pathologic | 1 | 2003 | 73 | 0.050 |
Why?
|
| Age of Onset | 2 | 2002 | 591 | 0.050 |
Why?
|
| Transfection | 2 | 2017 | 961 | 0.050 |
Why?
|
| Immersion | 1 | 2002 | 6 | 0.050 |
Why?
|
| Clot Retraction | 1 | 2002 | 6 | 0.050 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2003 | 57 | 0.050 |
Why?
|
| Physical Examination | 1 | 2004 | 170 | 0.050 |
Why?
|
| 3' Untranslated Regions | 2 | 2013 | 154 | 0.050 |
Why?
|
| Pregnancy | 1 | 2015 | 7476 | 0.050 |
Why?
|
| Cardiac Tamponade | 2 | 2005 | 35 | 0.050 |
Why?
|
| Heart Septum | 1 | 2002 | 41 | 0.050 |
Why?
|
| Catheter Ablation | 2 | 2004 | 322 | 0.050 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2004 | 193 | 0.050 |
Why?
|
| Case-Control Studies | 3 | 2002 | 3350 | 0.050 |
Why?
|
| Body Composition | 1 | 2004 | 544 | 0.040 |
Why?
|
| Streptozocin | 1 | 2021 | 25 | 0.040 |
Why?
|
| Homocysteine | 1 | 2002 | 116 | 0.040 |
Why?
|
| Corticosterone | 1 | 2021 | 49 | 0.040 |
Why?
|
| Health Personnel | 1 | 2006 | 539 | 0.040 |
Why?
|
| Esophagus | 1 | 2003 | 233 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 1069 | 0.040 |
Why?
|
| Ketones | 1 | 2021 | 25 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2018 | 1800 | 0.040 |
Why?
|
| Milrinone | 1 | 2001 | 30 | 0.040 |
Why?
|
| Venous Thrombosis | 1 | 2003 | 164 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2005 | 542 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2025 | 560 | 0.040 |
Why?
|
| Vascular Surgical Procedures | 1 | 2006 | 534 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2022 | 187 | 0.040 |
Why?
|
| Colloids | 1 | 2000 | 15 | 0.040 |
Why?
|
| Epinephrine | 1 | 2021 | 149 | 0.040 |
Why?
|
| Postoperative Care | 1 | 2002 | 293 | 0.040 |
Why?
|
| Water | 1 | 2021 | 185 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 2 | 1 | 2020 | 32 | 0.040 |
Why?
|
| Suction | 1 | 2000 | 45 | 0.040 |
Why?
|
| Mortality | 1 | 2022 | 264 | 0.040 |
Why?
|
| Radiotherapy | 1 | 2020 | 119 | 0.040 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 788 | 0.040 |
Why?
|
| Embolism, Air | 1 | 2000 | 21 | 0.040 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2020 | 93 | 0.040 |
Why?
|
| Ventricular Dysfunction | 1 | 2000 | 24 | 0.040 |
Why?
|
| Mass Screening | 2 | 2022 | 821 | 0.040 |
Why?
|
| Solubility | 1 | 1999 | 117 | 0.040 |
Why?
|
| Endocarditis | 1 | 2020 | 102 | 0.040 |
Why?
|
| Systole | 1 | 2000 | 195 | 0.040 |
Why?
|
| Kinetics | 1 | 2001 | 1087 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 2 | 1998 | 225 | 0.040 |
Why?
|
| Premedication | 1 | 1999 | 39 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2002 | 449 | 0.040 |
Why?
|
| Hemostasis | 1 | 2019 | 76 | 0.040 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2003 | 486 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 364 | 0.040 |
Why?
|
| Ulcer | 1 | 1999 | 50 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 1998 | 531 | 0.040 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2000 | 132 | 0.040 |
Why?
|
| Heart Valve Diseases | 1 | 2000 | 162 | 0.040 |
Why?
|
| Databases, Factual | 2 | 2020 | 1234 | 0.040 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 2 | 2009 | 3 | 0.040 |
Why?
|
| Denmark | 1 | 2018 | 28 | 0.040 |
Why?
|
| Disease Management | 1 | 2002 | 557 | 0.030 |
Why?
|
| Proprotein Convertase 9 | 1 | 2019 | 108 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2022 | 441 | 0.030 |
Why?
|
| Serum Albumin, Human | 1 | 1998 | 9 | 0.030 |
Why?
|
| Hematoma | 1 | 1999 | 85 | 0.030 |
Why?
|
| Soft Tissue Injuries | 1 | 1998 | 10 | 0.030 |
Why?
|
| Drug Monitoring | 1 | 2021 | 291 | 0.030 |
Why?
|
| Atherectomy, Coronary | 1 | 1997 | 7 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1999 | 129 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2004 | 978 | 0.030 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 111 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 1998 | 270 | 0.030 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 1998 | 122 | 0.030 |
Why?
|
| Saphenous Vein | 1 | 1997 | 49 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2007 | 2403 | 0.030 |
Why?
|
| Sudan | 1 | 1997 | 2 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2018 | 412 | 0.030 |
Why?
|
| Los Angeles | 1 | 1997 | 16 | 0.030 |
Why?
|
| Coroners and Medical Examiners | 1 | 1997 | 15 | 0.030 |
Why?
|
| Cats | 1 | 1997 | 114 | 0.030 |
Why?
|
| Emergency Treatment | 1 | 1998 | 78 | 0.030 |
Why?
|
| Tetrazolium Salts | 1 | 1997 | 10 | 0.030 |
Why?
|
| Oxidative Stress | 2 | 2017 | 788 | 0.030 |
Why?
|
| Mice, Obese | 1 | 2017 | 74 | 0.030 |
Why?
|
| Cytoprotection | 1 | 2017 | 36 | 0.030 |
Why?
|
| Cytochromes c | 1 | 2017 | 51 | 0.030 |
Why?
|
| Apolipoproteins E | 1 | 2017 | 187 | 0.030 |
Why?
|
| Data Collection | 1 | 1999 | 370 | 0.030 |
Why?
|
| Coenzymes | 1 | 1996 | 12 | 0.030 |
Why?
|
| Doxorubicin | 1 | 1998 | 288 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 1997 | 234 | 0.030 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2006 | 1167 | 0.030 |
Why?
|
| Hypercholesterolemia | 1 | 2019 | 230 | 0.030 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 1998 | 187 | 0.030 |
Why?
|
| Species Specificity | 1 | 1997 | 470 | 0.030 |
Why?
|
| Aging | 1 | 2024 | 1239 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2020 | 381 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 1997 | 308 | 0.030 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1998 | 218 | 0.030 |
Why?
|
| Sarcoma, Kaposi | 1 | 1998 | 128 | 0.030 |
Why?
|
| Cardiac Output, Low | 1 | 1996 | 58 | 0.030 |
Why?
|
| Cineradiography | 1 | 1996 | 2 | 0.030 |
Why?
|
| Running | 1 | 1996 | 32 | 0.030 |
Why?
|
| Coronary Care Units | 1 | 1996 | 34 | 0.030 |
Why?
|
| Electrodes | 1 | 1996 | 81 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 407 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 263 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 1996 | 235 | 0.030 |
Why?
|
| Long QT Syndrome | 1 | 1996 | 86 | 0.030 |
Why?
|
| Neutrophils | 1 | 1997 | 371 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 365 | 0.030 |
Why?
|
| Treatment Failure | 2 | 2007 | 348 | 0.030 |
Why?
|
| Genotype | 2 | 2017 | 2590 | 0.030 |
Why?
|
| Skin | 1 | 1998 | 544 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 567 | 0.030 |
Why?
|
| Rural Population | 1 | 1997 | 275 | 0.030 |
Why?
|
| Cytokines | 1 | 2020 | 1333 | 0.030 |
Why?
|
| Estradiol | 1 | 1996 | 460 | 0.030 |
Why?
|
| Purkinje Fibers | 1 | 1993 | 7 | 0.030 |
Why?
|
| Reperfusion | 1 | 1993 | 26 | 0.030 |
Why?
|
| Mitral Valve Prolapse | 1 | 1993 | 36 | 0.020 |
Why?
|
| Hyperhomocysteinemia | 2 | 2004 | 37 | 0.020 |
Why?
|
| Death, Sudden | 1 | 1993 | 45 | 0.020 |
Why?
|
| Serum Sickness | 1 | 1993 | 2 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2020 | 951 | 0.020 |
Why?
|
| Rats, Inbred Dahl | 1 | 2013 | 9 | 0.020 |
Why?
|
| Nebivolol | 1 | 2013 | 4 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 889 | 0.020 |
Why?
|
| Blood Coagulation Tests | 1 | 1993 | 65 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2013 | 25 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2013 | 140 | 0.020 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2013 | 32 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 3815 | 0.020 |
Why?
|
| Hypotension | 1 | 1994 | 187 | 0.020 |
Why?
|
| Antioxidants | 1 | 1995 | 330 | 0.020 |
Why?
|
| Thoracic Injuries | 1 | 1993 | 82 | 0.020 |
Why?
|
| Cineangiography | 2 | 2004 | 15 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2013 | 152 | 0.020 |
Why?
|
| Linear Models | 1 | 1994 | 687 | 0.020 |
Why?
|
| Activating Transcription Factor 2 | 1 | 2012 | 16 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2013 | 340 | 0.020 |
Why?
|
| Fatty Acids, Nonesterified | 1 | 2012 | 111 | 0.020 |
Why?
|
| Leptin | 1 | 2013 | 218 | 0.020 |
Why?
|
| Adiponectin | 1 | 2012 | 123 | 0.020 |
Why?
|
| Heart Arrest | 1 | 1996 | 355 | 0.020 |
Why?
|
| Jaundice | 1 | 1991 | 27 | 0.020 |
Why?
|
| Placebos | 1 | 2011 | 223 | 0.020 |
Why?
|
| Angiography | 2 | 2004 | 179 | 0.020 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2002 | 63 | 0.020 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1993 | 218 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 1133 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 2012 | 266 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2013 | 566 | 0.020 |
Why?
|
| Recombinant Proteins | 1 | 1993 | 1319 | 0.020 |
Why?
|
| Adrenergic beta-2 Receptor Antagonists | 1 | 2009 | 4 | 0.020 |
Why?
|
| Indomethacin | 1 | 1989 | 78 | 0.020 |
Why?
|
| Homozygote | 2 | 2002 | 533 | 0.020 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2009 | 50 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2008 | 29 | 0.020 |
Why?
|
| Cell Death | 1 | 2009 | 224 | 0.020 |
Why?
|
| Sepsis | 1 | 2012 | 493 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2014 | 770 | 0.020 |
Why?
|
| Hyperemia | 1 | 2007 | 30 | 0.020 |
Why?
|
| Phenotype | 1 | 2017 | 4483 | 0.020 |
Why?
|
| Vascular Resistance | 1 | 2007 | 182 | 0.020 |
Why?
|
| Vasodilation | 1 | 2007 | 175 | 0.020 |
Why?
|
| Ultrasonography, Doppler | 1 | 2007 | 187 | 0.010 |
Why?
|
| Organotechnetium Compounds | 1 | 2005 | 11 | 0.010 |
Why?
|
| Organophosphorus Compounds | 1 | 2005 | 25 | 0.010 |
Why?
|
| Internationality | 1 | 2006 | 128 | 0.010 |
Why?
|
| AC133 Antigen | 1 | 2005 | 34 | 0.010 |
Why?
|
| False Positive Reactions | 1 | 2005 | 142 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2005 | 57 | 0.010 |
Why?
|
| Isometric Contraction | 1 | 2005 | 23 | 0.010 |
Why?
|
| Cell Count | 1 | 2005 | 212 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2007 | 243 | 0.010 |
Why?
|
| Plasminogen Activators | 1 | 2004 | 17 | 0.010 |
Why?
|
| Safety | 1 | 2005 | 214 | 0.010 |
Why?
|
| Body Surface Area | 1 | 2004 | 36 | 0.010 |
Why?
|
| Telecommunications | 1 | 2004 | 21 | 0.010 |
Why?
|
| Unnecessary Procedures | 1 | 2004 | 61 | 0.010 |
Why?
|
| Aortography | 1 | 2004 | 154 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2004 | 176 | 0.010 |
Why?
|
| Ventricular Fibrillation | 1 | 2004 | 51 | 0.010 |
Why?
|
| Edema | 1 | 2004 | 130 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2005 | 409 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2005 | 345 | 0.010 |
Why?
|
| Adolescent | 1 | 2002 | 20893 | 0.010 |
Why?
|
| Ethanol | 1 | 2004 | 167 | 0.010 |
Why?
|
| Thallium Radioisotopes | 1 | 2001 | 4 | 0.010 |
Why?
|
| Radionuclide Ventriculography | 1 | 2001 | 4 | 0.010 |
Why?
|
| Cyclic Nucleotide Phosphodiesterases, Type 3 | 1 | 2001 | 3 | 0.010 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 2001 | 19 | 0.010 |
Why?
|
| Transducers | 1 | 2001 | 22 | 0.010 |
Why?
|
| Ventricular Pressure | 1 | 2000 | 34 | 0.010 |
Why?
|
| Retreatment | 1 | 2000 | 85 | 0.010 |
Why?
|
| Software | 1 | 2004 | 733 | 0.010 |
Why?
|
| Echocardiography, Doppler, Pulsed | 1 | 1999 | 15 | 0.010 |
Why?
|
| Gene Frequency | 1 | 1999 | 728 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1998 | 305 | 0.010 |
Why?
|
| Folic Acid | 1 | 1999 | 269 | 0.010 |
Why?
|
| Hot Temperature | 1 | 1998 | 137 | 0.010 |
Why?
|
| Patient Selection | 1 | 2001 | 724 | 0.010 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2000 | 325 | 0.010 |
Why?
|
| Fatal Outcome | 1 | 1998 | 349 | 0.010 |
Why?
|
| Aortic Diseases | 1 | 1999 | 186 | 0.010 |
Why?
|
| Tilt-Table Test | 1 | 1996 | 9 | 0.010 |
Why?
|
| Exercise Tolerance | 1 | 1996 | 91 | 0.010 |
Why?
|
| Diltiazem | 1 | 1994 | 13 | 0.010 |
Why?
|
| Verapamil | 1 | 1994 | 43 | 0.010 |
Why?
|
| Alleles | 1 | 1999 | 1673 | 0.010 |
Why?
|
| Young Adult | 1 | 2008 | 10042 | 0.010 |
Why?
|
| Electrophysiology | 1 | 1993 | 241 | 0.010 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 1991 | 11 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 1991 | 97 | 0.010 |
Why?
|
| Bilirubin | 1 | 1991 | 125 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 1999 | 3422 | 0.000 |
Why?
|
| Mutation | 1 | 2002 | 6080 | 0.000 |
Why?
|